image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Essentra - Acquires Clondalkin for US$455m

December 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • ESNT
  • Price:
  • 748p
Essentra, which makes small components from plastic, fibre and foam, has announced the US$455m (£284m) acquisition of Clondalkin, a leading global provider of speciality packaging for the pharmaceutical and health  care industries, part funded by a placing of new shares (10% of the share capital), which raised £169m.Clondalkin, which operates 24 facilities in North America and Europe, marks the second major foray into the growing healthcare segment following the £160m purchase of Contego in 2013. For the year ended 31 December, Clondalkin generated revenue of US$429m, EBITDA of US$55.5m and operating profit of US$37.2m, while synergies will be at least US$16m in 2016.Earlier, Essentra announced a strong ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X